# Initiative Capital Romandie

> Initiative Capital Romandie is a VC fund backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 6
- Last investment: Dec 2019
- Lead investor: 0%
- Last updated: Aug 2026

Initiative Capital Romandie is a private equity fund that focuses on technology companies based in Western Switzerland.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.8M–$10M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 33% |
| Biotechnology | 2 | 33% |
| Medical Device | 2 | 33% |
| Fitness | 1 | 17% |
| Medical | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Series B | 1 | 17% |
| Series E | 1 | 17% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aleva Neurotherapeutics | Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified. | $9.3M | Series E | Dec 16, 2019 |  |
| PicoDRILL | PicoDRILL generates technology leadership for its partner/customers through cutting-edge technology for drilling needs in the nanotechnology field. picoDrill is a private company located in Lausanne, Switzerland. | $6.8M | Series A | Aug 01, 2017 |  |
| Diagnoplex | Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as wellas its high sensitivity and specificity. | $1.5M |  | Jun 07, 2013 |  |
| Aleva Neurotherapeutics | Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified. | $10.4M | Series A | Aug 25, 2011 |  |
| Viroblock | Viroblock is a Swiss based company focused on developing a novel anti-viral technology that is both rapid acting and broad spectrum. Applied to non-woven fabric, the technology is particularly suited for air filtration products. In fact, previous work has shown Viroblock fabric to kill over 99% of H5N1 viruses when challenged in standardizedaerobiology experiments. |  | Series B | Feb 05, 2010 |  |
| Viroblock | Viroblock is a Swiss based company focused on developing a novel anti-viral technology that is both rapid acting and broad spectrum. Applied to non-woven fabric, the technology is particularly suited for air filtration products. In fact, previous work has shown Viroblock fabric to kill over 99% of H5N1 viruses when challenged in standardizedaerobiology experiments. |  | Series A | Jul 20, 2007 |  |

6 of 6 investments shown.

## Co-investors
- [BB Biotech Ventures](https://shizune.co/investors/profile/bb-biotech-ventures) — VC Fund, 2 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 2 deals together
- [Fongit Seed Invest](https://shizune.co/investors/profile/fongit-seedinvest) — VC Fund, 2 deals together
- [BlueOcean Ventures](https://shizune.co/investors/profile/blueocean-ventures) — VC Fund, 1 deal together
- [Debiopharm Innovation Fund](https://shizune.co/investors/profile/debiopharm-innovation-fund) — VC Fund, 1 deal together
- [Forrestal Capital](https://shizune.co/investors/profile/forrestal-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotechnology VC Funds in Switzerland](https://shizune.co/investors/biotechnology-vc-funds-switzerland)
- [Health Care VC Funds in Switzerland](https://shizune.co/investors/health-care-vc-funds-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Biotech VC Funds in Switzerland](https://shizune.co/investors/biotech-vc-funds-switzerland)
- [Medical Device Investors in Switzerland](https://shizune.co/investors/medical-device-investors-switzerland)

## FAQ

### What does Initiative Capital Romandie invest in?

Initiative Capital Romandie invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Initiative Capital Romandie's check size?

Initiative Capital Romandie typically joins rounds of $6.8M–$10M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Initiative Capital Romandie participates in.

### When did Initiative Capital Romandie last invest?

The most recent investment recorded for Initiative Capital Romandie closed in Dec 2019. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co